Advisory Committee on Heritable Disorders in Newborns and Children, 33136-33137 [2017-15113]
Download as PDF
33136
Federal Register / Vol. 82, No. 137 / Wednesday, July 19, 2017 / Notices
Expenditures. While separate in terms
of the data gathered, the financial
review and certification of funds
processes that are completed to generate
the information gathered on these forms
are generally done at the same time by
the States. To reduce burden, these
forms are being presented together for
renewal since both are issued under the
same Program Instruction, and they
have the same due date to ACL.
The Certification of Maintenance of
Effort under Title III and Certification of
Long-Term Care Ombudsman (LTCO)
Program Expenditures provide
statutorily required information
regarding each state’s contribution to
programs funded under the Older
Americans Act and compliance with
legislative requirements, pertinent
Federal regulations, and other
applicable instructions and guidelines
issued by ACL. This information will be
used for Federal oversight of Title III
Programs and Title VII Ombudsman
Program expenditures.
In addition to renewing OMB
approval of these data collection
instruments, minor changes are being
proposed to the LTCO Expenditures
Certification and an accompanying
document which provides specific
statutory references related to
Ombudsman program minimum
funding, non-supplanting requirements
and state authorization to expend Title
III–B funds on Ombudsman activities.
Specifically, changes include making
the reference to the Fiscal Year at the
bottom of the form a fillable field to
allow the date to be changed annually;
listing the ‘‘Administration for
Community Living (ACL)’’ as the
intended recipient of the completed
form; and updating statutory language
references (i.e., Section 306(a)(9))
Number of
respondents
Respondent/data collection activity
provided on the second page, to reflect
changes made during the 2016
reauthorization of the OAA.
ACL estimates the burden of this
collection of information as follows: 56
State Agencies on Aging respond
annually, and it takes each agency an
average of one half (1⁄2) hour per State
agency per year to complete each form
for a total of twenty-eight hours for all
state agencies annually. The half hour
estimate is based on prior years’
experience with States in completing
these forms.
The proposed data collection tools
may be found on the ACL Web site for
review at: https://www.acl.gov/sites/
default/files/programs/2017-06/
MOE%20and%20LTCO%
20Certification%202017%20%20FINAL.pdf.
Responses
per
respondent
(/year)
Hours per
response
Annual burden
hours
Certification on Maintenance of Effort under Title III .......................................
Certification of Long-Term Care Ombudsman Program Expenditures ...........
56
56
1
1
12
12
⁄
⁄
28
28
Total ..........................................................................................................
112
2
1
56
Dated: July 11, 2017.
Mary Lazare,
Acting Administrator and Assistant Secretary
for Aging.
[FR Doc. 2017–14962 Filed 7–18–17; 8:45 am]
BILLING CODE 4154–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Service
Administration
Advisory Committee on Heritable
Disorders in Newborns and Children
Health Resources and Service
Administration (HRSA), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, notice
is hereby given that a meeting is
scheduled for the Advisory Committee
on Heritable Disorders in Newborns and
Children (ACHDNC). This meeting will
be open to the public but advance
registration is required. Please register
online at https://
www.achdncmeetings.org/ by 12:00 p.m.
ET on August 1, 2017. Information
about the ACHDNC can be obtained by
accessing the following Web site:
asabaliauskas on DSKBBXCHB2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:49 Jul 18, 2017
Jkt 241001
https://www.hrsa.gov/
advisorycommittees/mchbadvisory/
heritabledisorders/.
DATES: The meeting will be held on
August 3, 2017, 9:30 a.m. to 5:00 p.m.
ET and August 4, 2017, 9:30 a.m. to 3:00
p.m. ET. Meeting times may be revised;
please check the Committee’s Web site
for updates.
ADDRESSES: This meeting will be held
in-person at 5600 Fishers Lane, 5th
Floor Pavilion, Rockville, MD 20857.
The meeting will also be accessible via
Webcast. Instructions on accessing the
meeting via Webcast will be provided
upon registration. Please note that 5600
Fishers Lane requires security screening
on entry. Visitors must provide a
driver’s license, passport, or other form
of government-issued photo
identification to be granted entry into
the facility. Non-US citizens planning to
attend in person will need to provide
additional information to HRSA by July
24, 2017, 12:00 p.m. EDT. Please see
contact information below.
FOR FURTHER INFORMATION CONTACT:
Anyone requesting information
regarding the ACHDNC should contact
Ann Ferrero, Maternal and Child Health
Bureau (MCHB), HRSA, in one of three
ways: (1) Send a request to the following
address: Ann Ferrero, MCHB, HRSA
5600 Fishers Lane, Room 18N100C,
PO 00000
Frm 00097
Fmt 4703
Sfmt 4703
Rockville, MD 20857; (2) call 301–443–
3999; or (3) send an email to: AFerrero@
hrsa.gov.
The
ACHDNC provides advice to the
Secretary of HHS on the development of
newborn screening activities,
technologies, policies, guidelines, and
programs for effectively reducing
morbidity and mortality in newborns
and children having, or at risk for,
heritable disorders. In addition,
ACHDNC’s recommendations regarding
inclusion of additional conditions and
inherited disorders for screening which
have been adopted by the Secretary are
then included in the Recommended
Uniform Screening Panel (RUSP).
Conditions listed on the RUSP
constitute part of the comprehensive
preventive health guidelines supported
by HRSA for infants and children under
section 2713 of the Public Health
Service Act, codified at 42 U.S.C. 300gg13. Under this provision, nongrandfathered health plans are required
to cover screenings included in the
HRSA-supported comprehensive
guidelines without charging a copayment, co-insurance, or deductible for
plan years (i.e., policy years) beginning
on or after the date that is 1 year from
the Secretary’s adoption of the
condition for screening.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\19JYN1.SGM
19JYN1
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Federal Register / Vol. 82, No. 137 / Wednesday, July 19, 2017 / Notices
The meeting agenda will include: (1)
Presentations and discussion on the
processes states use to identify and
follow up on out of range newborn
screening results; (2) a presentation on
phase one of the spinal muscular
atrophy evidence review; (3)
presentations on newborn screening
topics such as the clinical and public
health impact of Critical Congenital
Heart Defects, quality measures in
newborn screening, and a review of
newborn screening technology; and (4)
updates from the Laboratory Standards
and Procedures workgroup, Follow-up
and Treatment workgroup, and
Education and Training workgroup. The
Committee will not be voting on a
proposed addition of a condition to the
RUSP. Agenda items are subject to
change. The final meeting agenda will
be available 2 days prior to the meeting
on the Committee’s Web site: https://
www.hrsa.gov/advisorycommittees/
mchbadvisory/heritabledisorders.
Members of the public will have the
opportunity to provide comments. All
comments are part of the official
Committee record. To submit written
comments or request time for an oral
comment at the meeting, please register
online by 12:00 p.m. on July 28, 2017,
at https://www.achdncmeetings.org/. To
ensure all individuals who have
registered and requested time for oral
comments are accommodated, the
allocated time for comments may be
limited. Individuals associated with
groups or who plan to provide
comments on similar topics may be
asked to combine their comments and
present them through a single
representative. No audiovisual
presentations are permitted. Written
comments should identify the
individual’s name, address, email,
telephone number, professional or
organization affiliation, background or
area of expertise (i.e., parent, family
member, researcher, clinician, public
health) and the topic/subject matter.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify Ann Ferrero using the address
and phone number above at least 10
days prior to the meeting.
Jason E. Bennett,
Director, Division of the Executive Secretariat.
[FR Doc. 2017–15113 Filed 7–18–17; 8:45 am]
BILLING CODE 4165–15–P
VerDate Sep<11>2014
18:49 Jul 18, 2017
Jkt 241001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS
Notice.
AGENCY:
ACTION:
Notice is hereby given that
the Office of Research Integrity (ORI)
has taken final action in the following
case:
Alec Mirchandani, Florida Atlantic
University: Based on the report of the
inquiry conducted by Florida Atlantic
University (FAU), the Respondent’s
admission, and analysis conducted by
ORI, ORI found that Mr. Alec
Mirchandani, former post-baccalaureate
research volunteer in the Center for
Complex Systems and Brain Sciences,
Florida Atlantic University (FAU),
engaged in research misconduct in
research supported by National Institute
of Mental Health (NIMH), National
Institutes of Health (NIH), grant 1 R15
MH099590–01A1.
ORI found that Respondent engaged
in research misconduct by knowingly
and intentionally: (1) Fabricating the
results of the T-maze behavioral
experiment for control mice, (2)
falsifying the laboratory and vivarium
entry logs in an effort to cover up his
actions, and (3) reporting the fabricated
and falsified data to his laboratory
supervisors.
Specifically, ORI found that
Respondent knowingly and
intentionally:
• Fabricated the results that he
recorded for the T-maze behavioral
experiment in three of the five TMZ
control mice on the laboratory data
sheets and white board on fourteen (14)
of the sixteen (16) eligible days in June
2016, to make it appear as though he
had conducted the experiments;
• Falsified the animal transfer logs on
twelve (12) of the sixteen (16) eligible
days in June 2016, to make it appear as
though he had conducted the
experiments;
• Fabricated the times he recorded on
the laboratory data sheets on fourteen
(14) of the sixteen (16) eligible days in
June 2016, to make it appear as though
he had conducted the experiments;
• incorporated and recorded the
fabricated and falsified data with his
previous data in his laboratory notebook
and reported the results to his
laboratory supervisor and principal
investigator, such that the experimental
control data (five animals) for
experiments conducted from January
2016–June 30, 2016, were not accurately
represented.
SUMMARY:
PO 00000
Frm 00098
Fmt 4703
Sfmt 4703
33137
Mr. Mirchandani has entered into a
Voluntary Settlement Agreement with
ORI, in which he voluntarily agreed,
beginning on June 29, 2017:
(1) That if within two (2) years from
the effective date of the Agreement,
Respondent receives or applies for U.S.
Public Health Service (PHS) support,
Respondent agrees to have his research
supervised for a period of one (1) year,
beginning on the date of his
employment in a position in which he
receives or applies for PHS support, and
agrees to notify his employer(s)/
institution(s) of the terms of this
supervision. Respondent agrees that
prior to the submission of an
application for PHS support for a
research project on which the
Respondent’s participation is proposed
and prior to Respondent’s participation
in any capacity on PHS-supported
research, Respondent shall ensure that a
plan for supervision of Respondent’s
duties is submitted to ORI for approval.
The supervision plan must be designed
to ensure the scientific integrity of
Respondent’s research contribution.
Respondent agrees that he shall not
participate in any PHS-supported
research until such a supervision plan is
submitted to and approved by ORI.
Respondent agrees to maintain
responsibility for compliance with the
agreed upon supervision plan.
(2) To exclude himself voluntarily
from serving in any advisory capacity to
PHS including, but not limited to,
service on any PHS advisory committee,
board, and/or peer review committee, or
as a consultant for a period of one (1)
year, beginning with the effective date
of the Agreement.
FOR FURTHER INFORMATION CONTACT:
Director, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8200.
Kathryn M. Partin,
Director, Office of Research Integrity.
[FR Doc. 2017–15159 Filed 7–18–17; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
E:\FR\FM\19JYN1.SGM
19JYN1
Agencies
[Federal Register Volume 82, Number 137 (Wednesday, July 19, 2017)]
[Notices]
[Pages 33136-33137]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-15113]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Service Administration
Advisory Committee on Heritable Disorders in Newborns and
Children
AGENCY: Health Resources and Service Administration (HRSA), Department
of Health and Human Services (HHS).
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, notice
is hereby given that a meeting is scheduled for the Advisory Committee
on Heritable Disorders in Newborns and Children (ACHDNC). This meeting
will be open to the public but advance registration is required. Please
register online at https://www.achdncmeetings.org/ by 12:00 p.m. ET on
August 1, 2017. Information about the ACHDNC can be obtained by
accessing the following Web site: https://www.hrsa.gov/advisorycommittees/mchbadvisory/heritabledisorders/.
DATES: The meeting will be held on August 3, 2017, 9:30 a.m. to 5:00
p.m. ET and August 4, 2017, 9:30 a.m. to 3:00 p.m. ET. Meeting times
may be revised; please check the Committee's Web site for updates.
ADDRESSES: This meeting will be held in-person at 5600 Fishers Lane,
5th Floor Pavilion, Rockville, MD 20857. The meeting will also be
accessible via Webcast. Instructions on accessing the meeting via
Webcast will be provided upon registration. Please note that 5600
Fishers Lane requires security screening on entry. Visitors must
provide a driver's license, passport, or other form of government-
issued photo identification to be granted entry into the facility. Non-
US citizens planning to attend in person will need to provide
additional information to HRSA by July 24, 2017, 12:00 p.m. EDT. Please
see contact information below.
FOR FURTHER INFORMATION CONTACT: Anyone requesting information
regarding the ACHDNC should contact Ann Ferrero, Maternal and Child
Health Bureau (MCHB), HRSA, in one of three ways: (1) Send a request to
the following address: Ann Ferrero, MCHB, HRSA 5600 Fishers Lane, Room
18N100C, Rockville, MD 20857; (2) call 301-443-3999; or (3) send an
email to: AFerrero@hrsa.gov.
SUPPLEMENTARY INFORMATION: The ACHDNC provides advice to the Secretary
of HHS on the development of newborn screening activities,
technologies, policies, guidelines, and programs for effectively
reducing morbidity and mortality in newborns and children having, or at
risk for, heritable disorders. In addition, ACHDNC's recommendations
regarding inclusion of additional conditions and inherited disorders
for screening which have been adopted by the Secretary are then
included in the Recommended Uniform Screening Panel (RUSP). Conditions
listed on the RUSP constitute part of the comprehensive preventive
health guidelines supported by HRSA for infants and children under
section 2713 of the Public Health Service Act, codified at 42 U.S.C.
300gg-13. Under this provision, non-grandfathered health plans are
required to cover screenings included in the HRSA-supported
comprehensive guidelines without charging a co-payment, co-insurance,
or deductible for plan years (i.e., policy years) beginning on or after
the date that is 1 year from the Secretary's adoption of the condition
for screening.
[[Page 33137]]
The meeting agenda will include: (1) Presentations and discussion
on the processes states use to identify and follow up on out of range
newborn screening results; (2) a presentation on phase one of the
spinal muscular atrophy evidence review; (3) presentations on newborn
screening topics such as the clinical and public health impact of
Critical Congenital Heart Defects, quality measures in newborn
screening, and a review of newborn screening technology; and (4)
updates from the Laboratory Standards and Procedures workgroup, Follow-
up and Treatment workgroup, and Education and Training workgroup. The
Committee will not be voting on a proposed addition of a condition to
the RUSP. Agenda items are subject to change. The final meeting agenda
will be available 2 days prior to the meeting on the Committee's Web
site: https://www.hrsa.gov/advisorycommittees/mchbadvisory/heritabledisorders.
Members of the public will have the opportunity to provide
comments. All comments are part of the official Committee record. To
submit written comments or request time for an oral comment at the
meeting, please register online by 12:00 p.m. on July 28, 2017, at
https://www.achdncmeetings.org/. To ensure all individuals who have
registered and requested time for oral comments are accommodated, the
allocated time for comments may be limited. Individuals associated with
groups or who plan to provide comments on similar topics may be asked
to combine their comments and present them through a single
representative. No audiovisual presentations are permitted. Written
comments should identify the individual's name, address, email,
telephone number, professional or organization affiliation, background
or area of expertise (i.e., parent, family member, researcher,
clinician, public health) and the topic/subject matter.
Individuals who plan to attend and need special assistance, such as
sign language interpretation or other reasonable accommodations, should
notify Ann Ferrero using the address and phone number above at least 10
days prior to the meeting.
Jason E. Bennett,
Director, Division of the Executive Secretariat.
[FR Doc. 2017-15113 Filed 7-18-17; 8:45 am]
BILLING CODE 4165-15-P